EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Real life evidence of volanesorsen for familial chylomicronemia syndrome in Colombia

Alejandro Román-González, Alejandro Castellanos, Diego Perdomo, Christian Colón, Juan Jose Vargas, Carlos O Mendivil, Johnayro Gutierrez

Journal of Clinical Lipidology · 2025

DOI: 10.1016/j.jacl.2025.04.203 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Lipidology, 2025. Verfasst von Alejandro Román-González und 6 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology and Diabetes Section, Internal Medicine Department, Faculty of Medicine, Universidad de Antioquia, Antioquia, Colombia (Drs Román-Gonzá…. Hauptthemen laut MEDLINE: Hyperlipoproteinemia Type I, Oligonucleotides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Familial chylomicronemia syndrome (FCS) is an ultra-rare disorder associated with pathogenic variants in genes implicated in chylomicron metabolism such as LPL, APOA5, APOC2, GPIHBP1, and LMF1. Patients with FCS have severe hypertriglyceridemia complicated with recurrent episodes of pancreatitis. Volanesorsen is a treatment option for such patients. However, this treatment is not approved or available in all countries. OBJECTIVE: To present the real-life evidence of clinical response to volanesorsen in patients with FCS in Colombia. METHODS: All patients treated with volanesorsen in Colombia as of June 25, 2024, were included. After informed consent, relevant clinical and laboratory data were obtained through review of clinical charts and records from the volanesorsen patient support program. RESULTS: Ten patients with FCS and treated with volanesorsen were included. Most cases were caused by variants in LPL. A total of 90% of cases had at least 1 episode of pancreatis, the mean number of pancreatitis episodes was 5. Median follow-up was 56.5 weeks (IQR 38.3-82.3). The median highest plasma triglyceride (TG) level before treatment was 3111 mg/dL (IQR 1738-3810), while the median lowest TG level after treatment was 493 mg/dL (IQR 147-812). The mean percent decreases in plasma TG at months 1, 3, 6, and 12 were 53.6%, 59.7%, 51.5%, and 40.5%, respectively. There were no new pancreatitis episodes after initiation of volanesorsen treatment. Side effects were consistent with those reported in clinical trials. CONCLUSION: Real-life data of volanesorsen treatment for FCS in Colombia demonstrate efficacy and safety similar to pivotal clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hyperlipoproteinemia Type IOligonucleotidesHumansColombiaMaleFemaleAdultMiddle AgedTriglyceridesAdolescentLipoprotein LipaseYoung Adult

Stichwörter der Autor:innen

Familial chylomicronemia syndromePancreatitisTriglyceridesVolanesorsen

Substanzen

ISIS 304801OligonucleotidesTriglyceridesLipoprotein Lipase

Autor:innen und Institutionen

  • Endocrinology and Diabetes Section, Internal Medicine Department, Faculty of Medicine, Universidad de Antioquia, Antioquia, Colombia (Drs Román-González and Gutierrez); Hospital San Juan de Dios, Rionegro, Antioquia, Co…
  • Medicina Interna, Hospital San Jerónimo de Montería, Universidad del Sinú Elias Bechara Zainum, Montería, Colombia (Dr Castellanos).
  • Centros Médicos Colsanitas, Bogotá, Colombia (Dr Perdomo).
  • Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia (Dr Colón); School of Medicine, Universidad de los Andes, Colombia. Section of Endocrinology, Fundación Santa Fe de Bogotá, Colombia (Drs Colón and M…
  • Clínica Especializada La Concepción, Sincelejo, Colombia (Dr Vargas).
  • School of Medicine, Universidad de los Andes, Colombia. Section of Endocrinology, Fundación Santa Fe de Bogotá, Colombia (Drs Colón and Mendivil).

Zitieren

APA

Román-González, A., Castellanos, A., Perdomo, D., Colón, C., Vargas, J. J., Mendivil, C. O., & Gutierrez, J. (2025). Real life evidence of volanesorsen for familial chylomicronemia syndrome in Colombia. Journal of Clinical Lipidology. https://doi.org/10.1016/j.jacl.2025.04.203

Vancouver

Román-González A, Castellanos A, Perdomo D, Colón C, Vargas JJ, Mendivil CO, et al. Real life evidence of volanesorsen for familial chylomicronemia syndrome in Colombia. Journal of Clinical Lipidology. 2025. doi:10.1016/j.jacl.2025.04.203

BibTeX
@article{RomnGonzlez2025,
  author = {Román-González, Alejandro and Castellanos, Alejandro and Perdomo, Diego and Colón, Christian and Vargas, Juan Jose and Mendivil, Carlos O and Gutierrez, Johnayro},
  title = {Real life evidence of volanesorsen for familial chylomicronemia syndrome in Colombia},
  journal = {Journal of Clinical Lipidology},
  year = {2025},
  doi = {10.1016/j.jacl.2025.04.203}
}
Kostenlos starten →